The Endocrinology Network® Weight Management clinical resource center is the home of all content related to weight loss and obesity management. Now a full-blown epidemic, the obesity crisis is one of the most prominent and dangerous health crises in the US. This page will provide insight and perspective related to FDA approvals, the latest studies, and guideline updates related to nutrition, obesity, and weight management.
December 15, 2022
A systematic review and meta-analysis of studies reporting the pooled prevalence of obesity in pediatric type 2 diabetes suggest 75% of these patients had obesity.
December 06, 2022
Data from the BAPO trial suggests use of oral butyrate supplementation was associated with a 40% absolute increase in rate of the trial's BMI-based primary outcome at 6 months relative to placebo therapy in a population of pediatric patients with obesity.
December 02, 2022
Gregory Weiss, MD, provides perspective on how improved safety of these procedures has revolutionized the way clinicians view use of bariatric and metabolic surgeries as a method for inducing weight loss in people with overweight and obesity.
December 01, 2022
An analysis of survey data from more than 1400 adults in the UK provides insight into potential risk factors for developing long COVID symptoms, with results indicating both female sex and increased body mass index as potential risk factors.
November 30, 2022
Results of the DIRECT-PLUS trial provide clinicians with new insights into the impact of the Mediterranean diet and a modified Mediterranean diet as a method for inducing weight loss.
November 14, 2022
In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.
November 09, 2022
At AHA 2022, Diana Isaacs, PharmD, provides perspective on the potential impact of optimized uptake of newer obesity medications could have on population-level cardiovascular disease prevention.
November 02, 2022
Data from the STEP TEENS trial, which assessed the benefits of semaglutide 2.4 mg (Wegovy) in individuals aged 12-18 years with overweight or obesity, indicates use of the GLP-1 receptor agonist was associated with a mean reduction in body weight of 16% during the 68-week trial.
October 29, 2022
The October 2022 month in review recap includes a pair of studies that paint a grim picture related to the burden of diabetes in the US, a trio of new obesity guidelines/reports from major national and international organizations, and news related to the latest developments in the world of continuous glucose monitoring.
October 23, 2022
Published on October 21, the metabolic and bariatric surgery guideline considerations from the American Society of Metabolic and Bariatric Surgery and the International Federation for the Surgery of Obesity and Metabolic Disorders represent the first major updates to guidance since a National Institutes of Health document released in 1991.